Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Executive Summary

Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.

Advertisement

Related Content

Pharma-Related Probes Could Be Impacted By Departure Of US Attorneys
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Off-Label Promotion: 'Safe Harbor' Preferable To Expansive Free Speech Rulings
‘Who Is The Arbiter?’ US FDA Asks As It Mulls Loosening Off-Label Reins
Pharma's Medical Liaisons: From KOLs To Outcomes And Virtual Options
Industry's Off-Label Hearing Priorities Taking Shape
Off-Label Debate Between FDA, Industry To Formally Begin After Election

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel